Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.

12
Number of overlapping holdings
26.1%
% of IDNA's 51 holdings also in CANC
24.5%
% of CANC's 49 holdings also in IDNA
Overlap by Weight
Sector Drift (IDNA minus CANC)
Overlapping Holdings
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
Company | Weight in IDNA |
Weight in CANC |
Overlap | |
---|---|---|---|---|
REVOLUTION MEDICINES, INC. | 4.4% | 6.3% | 4.4% | |
ASTRAZENECA PLC | 5.3% | 4.3% | 4.3% | |
EXELIXIS INC | 5.3% | 3.9% | 3.9% | |
ARCELLX, INC. | 3.6% | 2.7% | 2.7% | |
MERCK & CO. INC. | 3.9% | 2.6% | 2.6% |
Position Highlights (Non-Overlapping Exposures)
IDNA Overweight Relative to CANC
BEIGENE, LTD. | 5.9% | |
GSK PLC | 5.6% | |
SANOFI-AVENTIS | 5.6% | |
ROCHE HOLDING LTD | 5.5% | |
SPRINGWORKS THERAPEUTICS, INC. | 5.3% | |
TAKEDA PHARMACEUTICAL CO LTD | 5.2% | |
GENMAB A/S | 4.7% | |
BIONTECH SE SPONSORED ADR | 4.0% | |
INCYTE CORP | 3.3% | |
BIOCRYST PHARMACEUTICALS INC | 3.3% |
IDNA Underweight Relative to CANC
ROCHE HOLDINGS LTD-SPONS ADR | -5.1% | |
ELI LILLY & CO | -4.8% | |
NOVARTIS AG | -4.3% | |
BRIDGEBIO PHARMA, INC. | -4.3% | |
NUVALENT, INC. CLASS A | -3.9% | |
SUMMIT THERAPEUTICS INC | -3.9% | |
BRISTOL-MYERS SQUIBB CO | -3.8% | |
GENMAB A/S SPONSORED ADR | -3.5% | |
ZAI LAB LTD. UNSPONSORED ADR | -3.1% | |
MERUS N.V. | -3.1% |